Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Sat, May 30, 2026 astatine 2:17 PM CDT 4 min read

On May 15, 2026, Madison Avenue Partners disclosed a caller presumption successful Indivior (NASDAQ:INDV), acquiring 4,315,162 shares successful the archetypal quarter—an estimated $142.51 cardinal commercialized based connected quarterly mean pricing.

What happened

According to its SEC filing dated May 15, 2026, Madison Avenue Partners opened a caller presumption successful Indivior (NASDAQ:INDV) during the archetypal 4th by acquiring 4,315,162 shares. The estimated worth of the commercialized was $142.51 million, calculated utilizing the mean unadjusted closing terms implicit the quarter. At quarter’s end, the involvement was valued astatine $131.53 million, reflecting some trading enactment and terms movements.

What other to cognize

This was a caller presumption for the fund, representing 5.72% of reportable U.S. equity assets nether absorption arsenic of March 31, 2026.
Top holdings aft the filing:
- NASDAQ: SNDK: $393.28 cardinal (17.1% of AUM)
- NYSE: GHC: $259.91 cardinal (11.3% of AUM)
- NYSE: CPNG: $176.79 cardinal (7.7% of AUM)
- NYSE: MICC: $171.11 cardinal (7.4% of AUM)
- NYSE: MKL: $168.23 cardinal (7.3% of AUM)
As of Friday, Indivior shares were priced astatine $36.02, up adjacent to 200% this past twelvemonth and good outperforming the S&P 500, which is alternatively up astir 28%.

Company overview

Metric

Value

Revenue (TTM)	$1.29 billion
Net income (TTM)	$252.00 million
Price (as of Friday)	$36.02

Company snapshot

INDV develops and markets buprenorphine-based medicine drugs, including Suboxone Film, Suboxone Tablet, and Subutex Tablet, chiefly for the attraction of opioid dependence.
The steadfast operates a specialty pharmaceuticals concern model, generating gross done the manufacture and merchantability of branded therapeutics crossed the United States, the United Kingdom, and planetary markets.
It serves healthcare providers, addiction attraction centers, and patients affected by opioid usage disorder.

Indivior is simply a specialty pharmaceutical institution focused connected addressing opioid dependence done proprietary buprenorphine-based therapies. The institution leverages its expertise successful addiction attraction and operates successful the United States, Rest of World, and United Kingdom markets.

What this transaction means for investors

Even with shares astir tripling implicit the past year, Madison Avenue Partners appears to judge the marketplace is inactive underestimating the durability of Indivior's opioid attraction franchise.

The biggest operator remains SUBLOCADE, the company's long-acting attraction for opioid usage disorder. First-quarter SUBLOCADE gross jumped 32% twelvemonth implicit twelvemonth to $232 million, helping propulsion full gross up 19% to $317 million. More importantly, profitability expanded adjacent faster. Adjusted EBITDA much than doubled to a grounds $164 million, and GAAP nett income climbed to $89 cardinal from $47 cardinal a twelvemonth earlier.

Management's confidence, meanwhile, showed up successful its actions. The institution raised full-year guidance, expects SUBLOCADE gross of up to $990 cardinal successful 2026, repurchased $125 cardinal of banal during the quarter, and inactive has $275 cardinal remaining nether its buyback authorization.

Going forward, the cardinal question is whether SUBLOCADE tin proceed taking stock successful a ample and underserved opioid attraction market, and the risk, of course, is concentration, fixed that overmuch of the concern lawsuit progressively rests connected 1 merchandise continuing to deliver.

Read Entire Article